These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 35266258)

  • 21. Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy.
    Wang LL; Patel G; Chiesa-Fuxench ZC; McGettigan S; Schuchter L; Mitchell TC; Ming ME; Chu EY
    JAMA Dermatol; 2018 Sep; 154(9):1057-1061. PubMed ID: 30027278
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pustular Lichenoid Eruptions Induced by Immune Checkpoint Inhibitors: Two Case Reports and a Review of the Literature.
    Emonet C; Tétart F; Bauvin O; Cellier L; Courville P; Mignard C; Janela-Lapert R; Lefebvre A; Lachkar S; Lechevalier D; Lagarce L; Carvalho P; Tedbirt B
    J Immunother; 2023 Feb-Mar 01; 46(2):59-63. PubMed ID: 36622668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-1 Inhibitor Induced Hypertrophic Lichen Planus: A Case Report.
    Lim O; Maher E; Miller DD
    Drugs R D; 2024 Jun; 24(2):353-357. PubMed ID: 38877280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful Use of Rituximab and Intravenous Gamma Globulin to Treat Checkpoint Inhibitor- Induced Severe Lichen Planus Pemphigoides.
    Brennan M; Baldissano M; King L; Gaspari AA
    Skinmed; 2020; 18(4):246-249. PubMed ID: 33050991
    [No Abstract]   [Full Text] [Related]  

  • 25. Pembrolizumab-Induced Lichen Planus Pemphigoides in a Patient with Metastatic Adrenocortical Cancer: A Case Report and Literature Review.
    Madan V; Marchitto MC; Sunshine JC
    Dermatopathology (Basel); 2023 Aug; 10(3):244-258. PubMed ID: 37606485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report.
    Mari R; Guerin M; Vicier C; Walz J; Bonnet N; Pignot G; Gravis G
    Front Immunol; 2022; 13():984132. PubMed ID: 36189265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autoantibodies in lichen planus pemphigoides react with a novel epitope within the C-terminal NC16A domain of BP180.
    Zillikens D; Caux F; Mascaro JM; Wesselmann U; Schmidt E; Prost C; Callen JP; Bröcker EB; Diaz LA; Giudice GJ
    J Invest Dermatol; 1999 Jul; 113(1):117-21. PubMed ID: 10417629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lichen planus--specific antigen in oral lichen planus and oral lichenoid drug eruptions.
    McCartan BE; Lamey P
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2000 May; 89(5):585-7. PubMed ID: 10807715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune checkpoint inhibitor-induced lichenoid drug eruption-sparing scar burns.
    Truong K; Chamberlin CV; Kim J; Carlino MS; Araujo RR
    Australas J Dermatol; 2024 Mar; 65(2):163-166. PubMed ID: 38009870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Childhood lichen planus pemphigoides: a case report and review of the literature.
    Cohen DM; Ben-Amitai D; Feinmesser M; Zvulunov A
    Pediatr Dermatol; 2009; 26(5):569-74. PubMed ID: 19840313
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Generalized lichen amyloidosis associated with chronic lichen planus.
    Hongcharu W; Baldassano M; Gonzalez E
    J Am Acad Dermatol; 2000 Aug; 43(2 Pt 2):346-8. PubMed ID: 10901719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lichen planus pemphigoides: a clinicopathological study of nine cases.
    Willsteed E; Bhogal BS; Das AK; Wojnarowska F; Black MM; McKee PH
    Histopathology; 1991 Aug; 19(2):147-54. PubMed ID: 1757068
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lichenoid Dermatitis From Interferon alpha-2a in a Patient With Metastatic Renal Cell Carcinoma and Seronegative HCV.
    Bush AE; Hymes SR; Silapunt S
    J Drugs Dermatol; 2017 Jul; 16(7):714-716. PubMed ID: 28697228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imatinib-induced lichen planus and lichenoid drug eruption: A report of three cases.
    Almheirat Y; Bouabdalla S; Daflaoui H; Zizi N; Dikhaye S
    J Cutan Pathol; 2023 May; 50(5):415-419. PubMed ID: 36789996
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists.
    Asarch A; Gottlieb AB; Lee J; Masterpol KS; Scheinman PL; Stadecker MJ; Massarotti EM; Bush ML
    J Am Acad Dermatol; 2009 Jul; 61(1):104-11. PubMed ID: 19539844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Captopril-induced lichen planus pemphigoides.
    Ben Salem C; Chenguel L; Ghariani N; Denguezli M; Hmouda H; Bouraoui K
    Pharmacoepidemiol Drug Saf; 2008 Jul; 17(7):722-4. PubMed ID: 18489011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coexisting lichen planus and bullous pemphigoid or lichen planus pemphigoides?
    Lang PG; Maize JC
    J Am Acad Dermatol; 1983 Jul; 9(1):133-40. PubMed ID: 6350379
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lichen planus and lichenoid dermatoses: Clinical overview and molecular basis.
    Tziotzios C; Lee JYW; Brier T; Saito R; Hsu CK; Bhargava K; Stefanato CM; Fenton DA; McGrath JA
    J Am Acad Dermatol; 2018 Nov; 79(5):789-804. PubMed ID: 30318136
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lichenoid drug eruption associated with imatinib mesylate therapy.
    Alexandris D; Alevizopoulos N; Marinos L; Kanellis G; Gakiopoulou C
    J Oncol Pharm Pract; 2023 Jan; 29(1):252-257. PubMed ID: 35473395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [How I explore ... a lichenoid drug reaction].
    Paquet P; Fraiture AL; Piérard-Franchimont C; Piérard GE
    Rev Med Liege; 2001 Dec; 56(12):855-8. PubMed ID: 11820040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.